BIOCYTOGEN-B2315.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, BIOCYTOGEN-B (2315.HK) trades at a P/E of 52.00x, P/B of 14.00x, P/S of 11.30x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 14th percentile over 3Y); P/B sits at the 82nd percentile over the trailing 10Y window (vs. 76th percentile over 3Y); P/S sits at the 62nd percentile over the trailing 10Y window (vs. 78th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 81st percentile within its industry and the 90th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 68.6 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. BIOCYTOGEN-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2315 · SEHK: 2315 · 2315
Want the full picture on whether BIOCYTOGEN-B (2315.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 52.00 | ||||||
| P/B (MRQ) | 14.00 | ||||||
| P/S (TTM) | 11.30 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |